Sugi Predict

Sugi Predict / Targets / SLC18A3

SLC18A3

Vesicular acetylcholine transporter · Q16572 · SLC18A3 on Sugi Atlas →

32,573 patent compounds predicted against SLC18A3, 15,823 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Vesamicol Vesamicol (SCHEMBL571598) 1.00 13/20
SCHEMBL557667 SCHEMBL557667 0.54 11/20
SCHEMBL407263 SCHEMBL407263 0.59 10/20
SCHEMBL337665 SCHEMBL337665 0.56 9/20
SCHEMBL96849 SCHEMBL96849 0.55 9/20
SCHEMBL42833 SCHEMBL42833 0.63 7/20
SCHEMBL190370 SCHEMBL190370 0.63 7/20
SCHEMBL447032 SCHEMBL447032 0.63 7/20
SCHEMBL790829 SCHEMBL790829 0.63 7/20
SCHEMBL42580 SCHEMBL42580 0.61 7/20
Hydrogen Peroxide Hydrogen Peroxide (SCHEMBL42934) 0.61 7/20
SCHEMBL463694 SCHEMBL463694 0.58 7/20
SCHEMBL779924 SCHEMBL779924 0.55 7/20
SCHEMBL238333 SCHEMBL238333 0.42 7/20
SCHEMBL447356 SCHEMBL447356 0.50 6/20
SCHEMBL525796 SCHEMBL525796 0.49 6/20
SCHEMBL2050 SCHEMBL2050 0.61 5/20
SCHEMBL496223 SCHEMBL496223 0.60 5/20
SCHEMBL447088 SCHEMBL447088 0.56 5/20
SCHEMBL60704 SCHEMBL60704 0.56 5/20

Clinical trials — most relevant to SLC18A3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration PHASE4COMPLETED
Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753) PHASE4COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD PHASE3COMPLETED
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia PHASE1/PHASE2RECRUITING
Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm PHASE1/PHASE2COMPLETED
Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2 PHASE1COMPLETED
Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1 PHASE1COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Development of Cognitive Assessment Tools in Parkinson Disease EARLY_PHASE1COMPLETED
Mechanisms of Vasovagal Syncope EARLY_PHASE1COMPLETED
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol nanUNKNOWN
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL) nanACTIVE_NOT_RECRUITING
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation nanRECRUITING
DaTSCAN Brain Scintigraphy and Psychotropic Treatments: Influence on Radiotracer Binding nanCOMPLETED
Visualising Cerebral and Peripheral Cholinergic Nerves in Patients With Dementia Lewy Bodies. nanCOMPLETED
Spinal Cord sTimulation thEraPy for Parkinson's Disease Patients With Gait Problems nanCOMPLETED
Stem Cell Study of Genetics and Drug Addiction nanCOMPLETED
Role of the Striatal Cholinergic System in the Pathophysiology of Dystonia nanCOMPLETED
Insulin Detemir in Obesity Management nanACTIVE_NOT_RECRUITING
Non-Invasive Brain Stimulation to Improve Language in Down Syndrome. nanRECRUITING
TRANSEURO Open Label Transplant Study in Parkinson's Disease nanCOMPLETED
Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder nanUNKNOWN
Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI nanCOMPLETED
Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI nanCOMPLETED
Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies nanCOMPLETED
I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers nanCOMPLETED
Prognostic Value of FP-CIT-SPECT in Parkinson´s Disease nanCOMPLETED
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia nanCOMPLETED
Autonomic Function in Patients With COPD nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC18A3 binder may also engage these)

ProteinNameSimilarity
Q62666 — 1.000 Q62666 →
O35304 — 1.000 O35304 →
P59845 — 0.995 P59845 →
P81721 — 0.984 P81721 →
Q08C75 — 0.983 Q08C75 →
Q91498 — 0.982 Q91498 →
Q91514 — 0.981 Q91514 →
P34711 — 0.981 P34711 →
P58873 — 0.977 P58873 →
Q5RAQ1 — 0.975 Q5RAQ1 →
Q8K0H7 — 0.975 Q8K0H7 →
P58872 — 0.973 P58872 →
A1Z7R6 — 0.973 A1Z7R6 →
Q9UIG8 — 0.973 Q9UIG8 →
A4K2N8 — 0.972 A4K2N8 →
P27922 — 0.972 P27922 →
Q8VC82 — 0.971 Q8VC82 →
Q1KKV8 — 0.971 Q1KKV8 →
P19754 — 0.971 P19754 →
Q1LZF7 — 0.971 Q1LZF7 →
Q8NBP5 — 0.971 Q8NBP5 →
Q6PDC8 — 0.971 Q6PDC8 →
Q96KK3 — 0.971 Q96KK3 →
A4K2M4 — 0.970 A4K2M4 →
Q8C0T7 — 0.970 Q8C0T7 →
ADRA2C Alpha-2C adrenergic receptor 0.970 landscape →
A4K2Q6 — 0.970 A4K2Q6 →
Q8R3L5 — 0.969 Q8R3L5 →
ADCY7 Adenylate cyclase type 7 (EC 4.6.1.1) (ATP py 0.969 landscape →
A4K2R3 — 0.969 A4K2R3 →